MedTrace Logo

ATAC - Arimidex, Tamoxifen Alone or in Combination

NCT00849030 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 9358

Last updated 2012-06-06

No results posted yet for this study

Summary

The aim of this study is to test whether Arimidex alone or in combination with Tamoxifen is beneficial in the treatment of breast cancer.

Conditions

Interventions

DRUG

Anastozole (Arimidex)

1mg, orally, once daily

DRUG

Tamoxifen (Nolvadex)

20mg, orally, once daily

DRUG

Anastozole (Arimidex) placebo

1mg, orally, once daily

DRUG

Tamoxifen (Nolvadex) placebo

20mg, orally, once daily

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1996-07-31
Primary Completion
2001-06-30
Completion
2010-04-30

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00849030 on ClinicalTrials.gov